Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 November 2022 | Story Lunga Luthuli | Photo Stephen Collett
Prof Francis Petersen
Rector and Vice-Chancellor, Prof Francis Petersen, delivering a recognition and celebratory message to 44 University of the Free State employees who have completed 20 years and more at the institution.

Speaking at the 2022 Long Service Recognition Awards, celebrating ‘the best’, University of the Free State (UFS) Rector and Vice-Chancellor, Prof Francis Petersen, said: “The event is a reminder that the people – the staff – are the university. You are the stars tonight.”

The annual awards ceremony, held in the Centenary Complex on the Bloemfontein Campus on 21 October 2022, is a flagship event for the UFS to recognise and celebrate staff members who have worked at the institution for 20 to 40 years and longer.

Thanking staff, including those who will be retiring at the end of this year, Prof Petersen said: “Thank you for the contribution you have made to the university. As staff, we are the custodians of the university, and while you are here – if you can – add one more brick to build a better institution that you can be proud of.”

Joining the event was Shadrack Shamane, Human Resources Business Partner in the Division of Human Resources, who has worked for the UFS for 40 years. 

He started as a Labourer in the then Department of Provisioning, and in 1992 he was promoted to Supervisor and Driver. 

Shamane said: “Staying at the UFS so long was for a good cause because of the opportunities offered for growth. Over the years, I managed to complete a Certificate in Labour Law in 2004, Advanced Certificate in 2006, and a Postgraduate Diploma in Labour Law in 2008.”

He is also serving as a full-time National Education, Health and Allied Workers' Union shop steward.

Also recognised at this year’s awards was Ilse de Beer, Officer in the Project Management Unit of ICT Services. Ilse joined the UFS in 1987 as a Computer Mainframe Operator responsible for monitoring the mainframe, backups, and printing.

De Beer said: “I started working at Computer Services with the Sperry mainframe in 1987 till the last IBM mainframe, growing with changes in ICT Service, and today we work with data centres.”

De Beer was born on the Bloemfontein Campus in 1967 in what used to be her home – the Vishuis Bond behind the Vishuis hostel. 

She said: “I grew up on campus; it was my playground and I had loads of fun times through the years. In 1975, we moved into our own house, which is now the Cairnhall Private Hospital.”

Closing the event, Prof Petersen said: “I also want to thank your partners and line managers who have stood by you, there has been a lot of input coming from them, providing the necessary support.”

He urged staff who will be retiring at the end of the year to look out for the launch of Vision 130 – ‘an elaboration of the strategic intent of the university to reposition itself for 2034, when it will commemorate its 130th anniversary.’

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept